The HY Lab is dedicated to advancing innovative cancer therapies, with a strong focus on translational research targeting cancer-specific mutations.
With industry-aligned support, our mission is to accelerate platform development and clinical translation.
Our work spans antibody screening and engineering, bispecific antibody development, and T-cell?based therapies.
In addition, we are committed to driving innovation in lab automation and integrating AI into biomedical research.
We are seeking a Research Scientist with a strong passion for translational cancer research and the ambition to develop cutting-edge therapeutic approaches for clinical application.
The ideal candidate will bring a solid background in a relevant scientific field, with preferred expertise in antibody development, T-cell therapy, or the application of AI in the life sciences.
Key Responsibilities
Drive research projects in antibody engineering, bispecific antibody design, or T-cell?based therapies.Contribute to platform development for clinical translation.Collaborate with cross-disciplinary teams on projects involving automation and AI integration.Troubleshoot and optimize experimental workflows.Support the growth of translational studies with potential for startup development.Job Requirements
PhD in Cancer Biology, Immunology, Biochemical Engineering, Computational Biology, or a related field.Strong knowledge of cancer biology, immunology, or computational biology.Hands-on experience with animal handling and immune cell culture is preferred.Prior experience in antibody development or T-cell therapy is highly desirable.Proficiency in wet lab techniques (flexible for computational biologists).Strong enthusiasm for translational research with a startup mindset.Excellent troubleshooting and problem-solving abilities.Proven teamwork and leadership experience.Ability to work independently with a proactive approach.Strong organizational skills, responsibility, and eagerness to learn.Advanced critical thinking, communication, and interpersonal skills.